The company has less than one quarter of cash runway at current burn rates, making near-term dilutive financing or a distressed sale highly likely. The strategic alternatives review increases the probability of a sale or reverse merger. Traders should monitor for a capital raise or M&A announcement, which could cause further dilution or a premium buyout.
Price Chart
Executive Summary
Ensysce Biosciences reported Q1 2026 results with a net loss of $3.6M, widening from a $1.9M loss in Q1 2025, driven by increased R&D spending on the PF614 Phase 3 trial. Cash burn reduced cash to just $0.7M at quarter-end, though a $2.0M financing tranche closed post-quarter. The company announced a formal review of strategic alternatives, including partnerships or licensing, which could signal a sale or restructuring.
Key Financial Metrics
Key Facts
- Cash and cash equivalents fell to $0.7M as of March 31, 2026, from $4.3M at December 31, 2025.
- Net loss attributable to common stockholders was $3.6M in Q1 2026 vs. $1.9M in Q1 2025.
- R&D expenses rose to $3.3M from $1.9M YoY, driven by PF614 Phase 3 trial costs.
- Federal grant revenue declined to $1.0M from $1.3M YoY.
- Post-quarter, the company closed a $2.0M convertible preferred stock financing tranche.
- Board initiated a formal review of strategic alternatives, including potential partnerships or licensing.
- Stockholders' equity turned negative to ($0.7M) from positive $2.9M at year-end 2025.
- Net loss per share improved to ($0.52) from ($1.39) due to share count changes, not operational improvement.
Financial Impact
Cash burn of $3.6M in the quarter, with only $0.7M remaining at quarter-end, implying less than one quarter of runway without additional financing.
Risk Factors
- Cash runway of less than one quarter without additional financing.
- Potential for significant dilution from further equity or convertible financings.
- Risk of Nasdaq delisting if stock price or equity falls below minimum requirements.
- Clinical trial failure or delay in PF614 Phase 3 could destroy remaining value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023810 |
| Document: form8-k.htm | 0001493152-26-023810 |
| Document: 0001493152-26-023810-index-headers.html | 0001493152-26-023810 |
| Document: 0001493152-26-023810-index.html | 0001493152-26-023810 |
| Document: 0001493152-26-023810.txt | 0001493152-26-023810 |
| 8-K Data (Synthetic) | 0001493152-26-023810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 4, 2026 20w ago | S-3 | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | 8-K | — | awaiting T+20 | — | — |
May 15, 2026 23w ago | 8-K | — | awaiting T+20 | — | — |
Apr 3, 2026 29w ago | 8-K | — | awaiting T+20 | — | — |
Mar 30, 2026 30w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers